Kane Biotech Presents revyve(TM) Data at Diabetic Foot and Southern Region Burn Conferences

Executive Summary

• Kane Biotech announced new clinical data showing its FDA‑cleared revyve® Antimicrobial Wound Gel achieved a 97% average percent area reduction (PAR) in diabetic foot ulcers within 4 weeks and complete closure in 8–12 weeks.
• Pre‑clinical burn studies demonstrated up to a six‑log (99.99 %–99.9999 %) pathogen reduction within 30 minutes and sustained antibiofilm activity for at least 7 days.
• The results were presented at two major U.S. medical conferences (DFCon 2025 and Southern Region Burn Conference), supporting Kane’s three‑pillar strategy to expand its wound‑care market presence in the United States.

Key Details

• Product: revyve® Antimicrobial Wound Gel & revyve® Antimicrobial Wound Gel Spray (U.S. FDA 510(k) cleared; Health Canada approved).
• Diabetic Foot Ulcer Clinical Data (DFCon 2025):
• Average PAR of 97% at 4 weeks vs. benchmark 40‑50%.
• Complete wound closure achieved in all cases within 8–12 weeks across a multi‑center series.
• Sustained infection control and reduced bacterial bioburden throughout healing.
• Burn Care Pre‑clinical Data (Southern Region Burn Conference):
• 99.99 %–99.9999 % reduction in burn‑associated pathogens within 30 minutes of application.
• Antibiofilm activity maintained for a minimum of 7 days post‑application.
• Strategic Pillars Highlighted:
  1. Conduct U.S.–based case series demonstrating clinical use of revyve®.
  2. Report data at leading U.S. wound and burn care meetings.
  3. Rebuild U.S. distributor and sales agent network.
• Quotes:
• Dr. Raymond Abdo: “The usage of revyve gel has helped my patient proceed with increased healing wounds by keeping bacteria and bioburden at bay for hard‑to‑heal ulcerations.”
• Dr. Peter Moyer: “revyve is a great product for diabetic ulcers… it promotes faster and more effective wound healing by managing biofilm.”
• Dr. Mack Drake: “revyve’s ability to achieve up to a six‑log reduction in microbial load within minutes, while maintaining antibiofilm protection for at least seven days, represents a significant advancement in burn wound management.”
• Dr. Robert Huizinga (Interim CEO): “These findings underscore revyve’s ability to improve upon the standard of care in both diabetic foot and burn management.”

Notable Quotes

• Dr. Robert Huizinga, Interim CEO: “revyve’s antibiofilm and antimicrobial technology continues to demonstrate its potential to transform wound healing outcomes.”